CXCR2 and hepatocellular carcinoma: Another study reveals that the blockade of MDSC infiltration in mice with primary HCC or colorectal cancer liver metastasis using CXCR2 inhibitor SB225002 can significantly improve anti-PD-1 immunotherapy and improve the survival rate of HCC-bearing mice [88].